UCB says it has launched in the UK a new pre-filled self-injecting device for its anti-inflammatory drug Cimzia that was designed in collaboration with patients. UCB says it has launched in the UK a ...
The autoinjector is based on core technology licensed from Bespak. UCB announced that EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended the use of Cimzia (certolizumab pegol) ...
Consort Medical plc ("Consort Medical", "Consort" or the "Group") (LSE: CSRT), notes the announcement from UCB, dated 26 October 2016, that the new certolizumab pegol (Cimzia®) AutoClicks® prefilled ...
Cimzia (certolizumab) is a prescription drug used to treat plaque psoriasis, Crohn’s disease, and some types of arthritis, including rheumatoid arthritis. It’s given as an injection under the skin.
A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion from the EMA. UCB developed the AutoClicks ...
Each of these conditions causes your immune system (the body’s defense against disease) to mistakenly attack healthy cells. Cimzia and Humira help prevent the immune system from doing this. The drugs ...
Cimzia (certolizumab) is a prescription drug used to treat some types of arthritis and other conditions. Cimzia can cause side effects that range from mild to serious. Examples include infection and ...
UCB announced today that it received approval from Japanese health authorities for CIMZIA® (certolizumab pegol) to treat plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic ...
UCB says it has launched in the UK a new pre-filled self-injecting device for its anti-inflammatory drug Cimzia that was designed in collaboration with patients. UCB says it has launched in the UK a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback